Sponsors (314)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Requires the FDA to tell a prospective generic drug sponsor, on request, whether a proposed generic with the same inactive ingredients is qualitatively and quantitatively the same as the listed drug and to explain any differences. Updates pediatric drug requirements and enforcement (including new rules for molecularly targeted pediatric cancer studies, new timelines for guidance, and a due‑diligence process before FDA enforcement), extends and studies the rare pediatric disease priority review voucher program, narrows orphan‑drug exclusivity scope, adjusts several program funding and reporting rules, gives the OPTN new duties and temporary fee authority, and creates an FDA office to work with Abraham Accords countries on regulatory convergence and technical assistance.
The bill aims to accelerate generic availability, strengthen pediatric research, improve transplant coordination, and increase regulatory transparency—trading off greater regulatory complexity, new federal and provider costs, potential proprietary and privacy risks, and changes to incentives for rare-disease development.
Generic-drug sponsors and patients: the bill requires clearer FDA determinations on whether a generic is pharmaceutically the same, reducing approval uncertainty for manufacturers and likely speeding availability of lower-cost generics for patients.
Medicare beneficiaries and hospitals: provides a $3.047 billion increase to the Medicare Improvement Fund in the covered year, which could strengthen Medicare program solvency or support improved services and predictable Medicare-related funding for providers.
Children, pediatric cancer patients, and clinical researchers: tightens and clarifies pediatric-study design and reporting rules, sets deadlines for FDA guidance, mandates GAO/HHS oversight, and provides multi-year funding to support pediatric drug studies—together improving prospects for clinically meaningful pediatric dosing and safety data.
Generic and innovator drug developers: the process for declaring sameness could disclose formulation details that are commercially sensitive, risking proprietary information and competitive harm for some manufacturers.
Patients and taxpayers: requiring binding sameness determinations after ANDA submission and adding formal procedures could increase FDA workload, litigation risk, and the chance that an incorrect determination is preserved—potentially slowing other FDA activities and creating safety or cost risks.
Taxpayers and beneficiaries: the $3.047 billion appropriation increases federal spending in the year provided and, if not efficiently targeted, may produce limited direct benefits to beneficiaries despite the fiscal cost.
Introduced February 12, 2025 by Michael T. McCaul · Last progress December 2, 2025